• 1
  • 2
  • 3
  • 4
  • 5
Technology Offers


Technology Offers

About us

MBM ScienceBridge GmbH evaluates, protects and commercializes inventions of higher education institutions and research facilities. It was founded as a private company and wholly owned subsidiary of the University of Göttingen Public Law Foundation in 2004.

We see our mission in the motivation of scientists to also look at their own research results from the perspective of an economically relevant invention and to report such to the employer as an employee invention.

In the case of promising inventions, we coordinate the application for an intellectual property right with external patent lawyers who are specialised in the relevant field

We subsequently present such inventions worldwide to companies in order to identify partners who are interested in developing the invention into a product and placing the product onto the market

Göttingen, 13.10.2020


Scientists at the University of Göttingen develop drug for antibody tumour therapy

Chemists at the University of Göttingen have developed new cytotoxic drugs which could revolutionise antibody-based tumour therapy approaches. The research team succeeded in modifying the natural product Duocarmycin into “prodrug” formats – which means that it only develops its effect once inside the tumour cell, thus reducing the likelihood of potential side effects on passage through the body. The University has entered into an exclusive licence agreement with the biotechnology company Iksuda Therapeutics for onward development and commercialisation in cancer therapeutics.

Antibody tumour therapies have enabled significant therapeutic benefits to patients suffering from cancer, autoimmune diseases and other serious diseases. However, many antibodies lack sufficient anti-tumour activity in the cell. This can be achieved by the use of antibody-drug conjugates (ADCs), where antibodies, which target specific cancer antigens, are armed with powerful cell-killing (cytotoxic) agents or ‘payloads’. ADCs have become powerful additions to the cancer treatment armoury, with several recent drug approvals and expanding clinical validation. However, most early-wave ADCs are associated with poor tolerability profiles, often due to a reduction in efficacy caused by the loss of the toxic payload whilst in circulation. Some programmes have failed as a result of low efficacy, where the payload is not active enough once inside the cell. ADC innovators, such as Iksuda, are working on the development of ADCs with a higher therapeutic index and finding safer ways to deliver potent cell-killing toxins. Iksuda has developed their own stable conjugation platform which reduces the risk of loss of efficacy.
One way to enhance both safety and efficacy of an ADC is to ensure that the payload is only released via tumour-activated mechanisms. With this approach, the precursors, called prodrugs, are able to release more potent payloads inside the cancer cell, with limited impact outside the cell.

Continue Reading

Göttingen, 08.09.2017

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing. This lab innovation is based on previous scientific work from the group of Prof. Dr. Wolfram-Hubertus Zimmermann, Director of the Institute for Pharmacology and Toxicology at the UMG. Under the terms of the non-exclusive license agreement UMG will receive an upfront payment and, besides royalties, annual minimum license fees.


Continue Reading

Our Partners

   

Looking for innovation

MBM ScienceBridge GmbH supports scientists, evaluates inventions, oversees applications for intellectual property rights and out-licenses patents of universities and research institutions in Göttingen and Lower Saxony.

Our company evaluates, protects and commercializes inventions of higher education institutions and research facilities. It was founded as a private company and wholly owned subsidiary of the University of Göttingen Public Law Foundation in 2004.


Office of MBM ScienceBridge GmbH:
The office of the MBM ScienceBridge GmbH resides in the Laser Laboratory on the northern campus of the Georg-August-University Göttingen.

A subsidiary of